de Mendoza C - Search Results

1

Screening for HTLV-1 infection should be expanded in Europe.

Soriano V, de Mendoza C; Spanish HTLV Network. Soriano V, et al. Among authors: de mendoza c. Int J Infect Dis. 2024 Mar;140:99-101. doi: 10.1016/j.ijid.2024.01.015. Epub 2024 Feb 1. Int J Infect Dis. 2024. PMID: 38307379 Free article.

2

Comparison of three different commercial methods for measuring plasma viraemia in patients infected with non-B HIV-1 subtypes.

Holguín A, de Mendoza C, Soriano V. Holguín A, et al. Among authors: de mendoza c. Eur J Clin Microbiol Infect Dis. 1999 Apr;18(4):256-9. doi: 10.1007/s100960050273. Eur J Clin Microbiol Infect Dis. 1999. PMID: 10385013

3

Association between submaximal suppression of HIV replication and use of drug combinations without protease inhibitors.

de Mendoza C, Soriano V, González-Lahoz J. de Mendoza C, et al. Eur J Clin Microbiol Infect Dis. 1999 Aug;18(8):604-5. doi: 10.1007/s100960050358. Eur J Clin Microbiol Infect Dis. 1999. PMID: 10517203 No abstract available.

4

Prevalence of the HIV protease mutation N88S causing hypersensitivity to amprenavir.

Gallego O, Corral A, de Mendoza C, Soriano V. Gallego O, et al. Among authors: de mendoza c. Clin Infect Dis. 2002 May 1;34(9):1288-9. doi: 10.1086/339953. Clin Infect Dis. 2002. PMID: 11941567 No abstract available.

5

Genetic mechanisms of resistance to NRTI and NNRTI.

Soriano V, de Mendoza C. Soriano V, et al. Among authors: de mendoza c. HIV Clin Trials. 2002 May-Jun;3(3):237-48. doi: 10.1310/hct.2002.3.3.008. HIV Clin Trials. 2002. PMID: 12032883 Review.

6

Genetic mechanisms of resistance to protease inhibitors and entry inhibitors.

Soriano V, de Mendoza C. Soriano V, et al. Among authors: de mendoza c. HIV Clin Trials. 2002 May-Jun;3(3):249-57. doi: 10.1310/hct.2002.3.3.009. HIV Clin Trials. 2002. PMID: 12032884 Review.

7

Mechanisms of resistance to antiretroviral drugs--clinical implications.

de Mendoza C, Gallego O, Soriano V. de Mendoza C, et al. AIDS Rev. 2002 Apr-Jun;4(2):64-82. AIDS Rev. 2002. PMID: 12152520 Review.

8

Salvage treatment with lopinavir/ritonavir (Kaletra) in HIV-infected patients failing all current antiretroviral drug families.

de Mendoza C, Martín-Carbonero L, Barreiro P, Diaz B, Valencia E, Jiménez-Nácher I, Gallego O, Núñez M, González-Lahoz J, Soriano V. de Mendoza C, et al. HIV Clin Trials. 2002 Jul-Aug;3(4):304-9. doi: 10.1310/h5jn-mfg3-g35k-qx9j. HIV Clin Trials. 2002. PMID: 12187504

9

Decline in the rate of genotypic resistance to antiretroviral drugs in recent HIV seroconverters in Madrid.

de Mendoza C, del Romero J, Rodríguez C, Corral A, Soriano V. de Mendoza C, et al. AIDS. 2002 Sep 6;16(13):1830-2. doi: 10.1097/00002030-200209060-00019. AIDS. 2002. PMID: 12218398

10

Impact of HIV genotyping and drug levels on the response to salvage therapy with saquinavir/ritonavir.

Valer L, De Mendoza C, De Requena DG, Labarga P, García-Henarejos A, Barreiro P, Guerrero F, Vergara A, Soriano V; Fortogene Spanish Study Group. Valer L, et al. Among authors: de requena dg, de mendoza c. AIDS. 2002 Sep 27;16(14):1964-6. doi: 10.1097/00002030-200209270-00016. AIDS. 2002. PMID: 12351959 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

290 results

Search Page